We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Braveheart Investment Group Plc | LSE:BRH | London | Ordinary Share | GB00B13XV322 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.65 | -9.29% | 6.35 | 6.20 | 6.50 | 7.00 | 6.35 | 7.00 | 404,663 | 15:50:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Management Services | 51k | 1.59M | 0.0249 | 2.55 | 4.05M |
TIDMBRH
RNS Number : 0789B
Braveheart Investment Group plc
31 May 2023
31 May 2023
Braveheart Investment Group plc
("Braveheart", the "Company" or the "Group")
Investment update - Phasefocus Holdings Limited
Braveheart Investment Group (AIM: BRH), announces an update on Phasefocus Holdings Limited ("Phasefocus"), a company within Braveheart's investment portfolio and in which the Company has a 44.2% holding.
Phasefocus' imaging and analysis system, Livecyte(R), uses a novel method for high fidelity quantitative imaging and microscopy; this is known in the scientific literature as "ptychography".
Phasefocus recently appointed Nexus Scientific, a specialist in cell analysis instrument sales, to represent Livecyte(R) products in North America. Over the coming months, Nexus will be running a series of customer workshops, conference attendances and seminars, with the object of raising the profile and sales of Livecyte (R) in the USA .
Dr. Peter Djali has been appointed as Phasefocus's Head of European Business Development. Peter has previously held senior commercial roles in a range of biotech instrumentation companies, including Lumicks, CytoSMART, Isoplexis and Essen Bioscience. He brings with him a wealth of market sector experience and relevant potential customer connections. Peter will be building Phasefocus's sales channel network within Europe.
In April and May, Martin Humphry, CEO of Phasefocus, visited its distributors in Japan, China and the USA to raise the profile of Phasefocus and meet many potential customers.
Two new Livecyte(R) applications have been developed and are scheduled for launch before the end of 2023. These will be marketed as proprietary assays, to meet the needs of cell biologists testing drug performance in immuno-oncology and neurosciense applications. Livecyte (R) users have the ability to continuously track thousands of individual cells and sustain cell health and viability over prolonged durations. This fundamental feature facilitates longitudinal studies involving live cells, thereby permitting a more thorough exploration of dynamic cellular processes and the efficacy of drugs on them.
Trevor Brown, Chief Executive Officer of Braveheart, commented:
"Phasefocus has gained momentum in a number of areas recently which your Board is hopeful will lead to increased sales over the coming months."
For further information:
Braveheart Investment Group plc Tel: 01738 587555 Trevor Brown, Chief Executive Officer Viv Hallam, Executive Director Allenby Capital Limited (Nominated Tel: 020 Adviser and Joint Broker) 3328 5656 James Reeve / George Payne Peterhouse Capital Limited (Joint Tel: 020 Broker) 7469 0936 Duncan Vasey / Lucy Williams
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
UPDDZGFKVGZGFZM
(END) Dow Jones Newswires
May 31, 2023 02:00 ET (06:00 GMT)
1 Year Braveheart Investment Chart |
1 Month Braveheart Investment Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions